It would be of great interest to monitor neuroendocrine parameters such as beta-endorphins (to evaluate the state of well-being), blood or salivary cortisol levels (stress indicators) and the plasma concentration of some proinflammatory cytokines (TNF-alpha, IL-6, IL-1-beta and IFN-gamma), which are particularly relevant in Alzheimer’s disease, whose assessment could provide useful indications on AAT efficacy and, above all, a preliminary insight on its action mechanisms. The gene discussed is IL6; the disease is early-onset autosomal dominant Alzheimer disease.